We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
HISTOPATHOLOGY OF LIVER BY TEMOZOLOMIDE DRUG.
- Authors
Abdul Hassan, Saif Salah; Naeem, Noor Tariq; Nasri, Marwah Mohammed
- Abstract
The new drug, Temozolomide has been promising in the treatment of malignant gliomas and other tumours. Temozolomide is a new class of imidazotetrazine second-generation medications spontaneously converted into the active alkylating agent under physiological conditions. Use 30 of male albino rats for this purpose, divided into 3 groups, consisting of 10 rats in each group. A physiologic solution (normal saline 0.9 percent) was injected in Group 1 (controls), the drug was given to group 2 for 50 mg/kg/b.w/weekly and drug was received in group 3 for 12 weeks, with 80 mg/kg/b.w/weekly. The animals were killed at the end of the dose, the liver was excised for histologica. Histological exam of Temozolomide group liver tissues showed that histopathological changes increased with the increased dose of the treatments compared with the control group such as shows chronic hepatic edema around blood vessels with fibrosis. As well as there is chronic hepatic edema around blood vessels with fibrosis. Hepatocyte necrosis with ballooning degeneration in hepatocyte. Analysis of DNA damage through the use of the comet assessment kit. This result of comet assay showed that damage in DNA of liver cells at 12 weeks of treatment with Temozolomide different doses in four parameters comet high, comet medium, comet low and no damage. With 50 mg/kg and 75 mg/kg of Temozolomide groups increase in comet high, comet medium percentage, decrease in comet low and no damage percentage. The result of the present study indicated that 50 mg/kg/b.w. and 75 mg/kg/b.w. doses of Temozolomide able to induce male albino rats’ DNA liver damage. The new drug, Temozolomide has been promising in the treatment of malignant gliomas and other tumours. Temozolomide is a new class of imidazotetrazine second-generation medications spontaneously converted into the active alkylating agent under physiological conditions. Use 30 of male albino rats for this purpose, divided into 3 groups, consisting of 10 rats in each group. A physiologic solution (normal saline 0.9 percent) was injected in Group 1 (controls), the drug was given to group 2 for 50 mg/kg/b.w/weekly and drug was received in group 3 for 12 weeks, with 80 mg/kg/b.w/weekly. The animals were killed at the end of the dose, the liver was excised for histologica. Histological exam of Temozolomide group liver tissues showed that histopathological changes increased with the increased dose of the treatments compared with the control group such as shows chronic hepatic edema around blood vessels with fibrosis. As well as there is chronic hepatic edema around blood vessels with fibrosis. Hepatocyte necrosis with ballooning degeneration in hepatocyte. Analysis of DNA damage through the use of the comet assessment kit. This result of comet assay showed that damage in DNA of liver cells at 12 weeks of treatment with Temozolomide different doses in four parameters comet high, comet medium, comet low and no damage. With 50 mg/kg and 75 mg/kg of Temozolomide groups increase in comet high, comet medium percentage, decrease in comet low and no damage percentage. The result of the present study indicated that 50 mg/kg/b.w. and 75 mg/kg/b.w. doses of Temozolomide able to induce male albino rats’ DNA liver damage.
- Subjects
FIBROSIS; TEMOZOLOMIDE; GLIOMAS; ALKYLATING agents; HISTOPATHOLOGY
- Publication
Biochemical & Cellular Archives, 2021, Vol 21, Issue 2, p4933
- ISSN
0972-5075
- Publication type
Article